Compare seven editing and discovery approaches without confusing regulation, sequence editing, prediction and experimental proof.
Target, cell type, perturbation direction, delivery, durability and acceptable outcomes decide whether a method is suitable. No DNA sequence change does not establish instant reversibility or no risk.
All seven approaches shown.
What follows when a defined gene function is disrupted?
Useful for causal loss-of-function research and selected disease models.
Boundary: The guide locates a target, but cellular repair helps determine the result. Intended and unintended outcomes require measurement.
Does reducing expression improve the chosen function?
Lets a study ask about gene activity without equating repression with deletion.
Boundary: No DNA sequence change does not establish no risk or instant reversibility. Cell identity and persistence still matter.
Could increasing a protective program improve function?
A route to testing activity restoration and context-dependent response.
Boundary: Increasing a gene can have broad effects. More proliferation or weaker growth checkpoints is not necessarily healthier biology.
Could a regulatory change persist usefully without loss of identity?
Useful for questions about durable gene control and compact regulatory systems.
Boundary: Persistence can be a liability as well as a benefit. Delivery and controllability must be established in the intended tissue.
Is a defined causal sequence defect compatible with the editor?
A candidate when the intended change fits the system.
Boundary: No deliberate double-strand break does not mean no unintended outcomes. Sequence and tissue constraints remain.
Can the required change and delivery context be supported?
Supports a broader set of precise sequence questions; advanced systems explore larger changes.
Boundary: Prediction, efficiency, unintended outcomes, delivery and commercial software rights need separate assessment.
Which perturbations alter the measured phenotype in this model?
Connects a target with an experimental effect rather than association alone.
Boundary: A hit ranking does not independently validate target biology. Model choice, confounders and orthogonal evidence determine interpretation.
Scientific summaries are adapted from the supplied 15 October 2026 CRISPR Project Assessment. Source records show the original references and review access; this release is not a new systematic review.
C04 — Yu T, Ji M, Yu D, et al. Structure-guided discovery and engineering of miniature CRISPR–Cas12m for epigenome editing. Nature Structural & Molecular Biology. 16 September 2026.C05 — Hsu A, Chen PJ, Li AH, et al. Mechanistic machine learning for prediction of prime editing outcomes. Nature Biotechnology. 12 August 2026.C06 — Madsen A, Selfjord N, Martinez-Lage M, et al. Single-cell and in vivo profiling reveal heterogeneous and organ-specific CRISPR-Cas9 off-target and translocation outcomes. Nature Communications. 26 August 2026;17:9067.C09 — Jung H, Jeong B, Kim YW, et al. Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. 28 August 2026.C10 — Gu D, Kim GWD, Park M, et al. Abasic CRISPR RNAs inherently harness fidelity of SpCas9 for genome editing. Nature Chemical Biology. 5 February 2026.C12 — Lai C, Fu W, Liu J, et al. LMO7-mediated POLR2A degradation promotes cellular senescence through the MDM4/p53/p21 axis. Cell Death & Disease. 28 March 2026;17:421.C14 — Jiang AY, Cristian A, Brooks DL, et al. Efficient prime editing in vivo and in vitro using lipid nanoparticles. Nature Nanotechnology. 15 June 2026;21:1022–1035.C22 — Henard JM, Lee SA, Yu YC, Shao D, Azad RK, Henard CA. CRISPRi-based functional genomic screening identifies genes essential for CH4-dependent growth in a methanotrophic bacterium. Science Advances. 24 April 2026;12:eaed4234.